“Excellent scientific advice provided for the study design. Studies tailored for small biotechs with limited budget. Timelines met, rigor in execution. Indeed, a great partner for drug development in the metabolic disease area.”
Recent News
- Physiogenex to exhibit at booth#51 and present a new DIO NASH mouse study at the ILC-EASL 2022 in London, UK on June the 25th, 2022 06/21/2022
- Physiogenex to present the effects of clinical benchmarks in its obese NASH hamster model at the Keystone Symposia “Tissue Fibrosis and Repair”, June 12-16, Keystone, CO, USA 06/10/2022
- Physiogenex to present a new DIO NASH mouse study at the American Diabetes Association 2022 in New Orleans, LA, USA on June the 6th, 2022 06/02/2022
- Physiogenex to present the effects of clinical benchmarks in its obese NASH hamster model at the Global NASH conference in London May 26-27th, 2022 05/23/2022
- Physiogenex to present its obese/type 2 diabetic rat models of nephropathy at 59th ERA congress in Paris, France 05/13/2022
- Physiogenex to present its obese hamster model of severe COVID-19 at Vascular Discovery 2022 in Seattle, WA, USA 05/03/2022